Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: A post hoc analysis of the MEGA Study

Journal of Cardiology

Volumn 61, Issue 3, 2013, Pages 196-200

  Nishiwaki, Masato ^a   Ikewaki, Katsunori ^b   Ayaori, Makoto ^b   Mizuno, Kyoichi ^c   Ohashi, Yasuo ^d   Ohsuzu, Fumitaka ^b   Ishikawa, Toshitsugu ^e   Nakamura, Haruo ^f  

^a Keyaki Naika Clinic   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KANAGAWA INSTITUTE OF TECHNOLOGY   (Japan)

^f Mitsukoshi Health and Welfare Foundation   (Japan)

Author keywords

Cardiovascular disease; Coronary heart disease; Dyslipidemia; Phenotype; Pravastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIET; DISEASE CLASSIFICATION; DYSLIPIDEMIA; ELECTROPHORESIS; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHENOTYPE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; ELECTROPHORESIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHENOTYPE; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK REDUCTION BEHAVIOR; TIME FACTORS;

EID: 84875238038     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.10.005     Document Type: Article

References (19)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study Group.
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
5. Faergeman O., Holme I., Fayyad R., Bhatia S., Grundy S.M., Kastelein J.J., LaRosa J.C., Larsen M.L., Lindahl C., Olsson A.G., Tikkanen M.J., Waters D.D., Pedersen T.R. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009, 104:459-463.
6. Fredrickson D.S., Levy R.I., Lees R.S. Fat transport in lipoproteins-an integrated approach to mechanisms and disorders. N Engl J Med 1967, 276:273-281.
7. Rubenfire M., Brook R.D., Rosenson R.S. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 2010, 123:892-898.
8. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004, 68:860-867. Management of Eleveted Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group.
9. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., Mizuno K., Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163.
10. Mizuno K., Nakaya N., Ohashi Y., Tajima N., Kushiro T., Teramoto T., Uchiyama S., Nakamura H. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study). Circulation 2008, 117:494-502.
11. Ishikawa T., Mizuno K., Nakaya N., Ohashi Y., Tajima N., Kushiro T., Teramoto T., Uchiyama S., Nakamura H. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circ J 2008, 72:1576-1582.
12. Tajima N., Kurata H., Nakaya N., Mizuno K., Ohashi Y., Kushiro T., Teramoto T., Uchiyama S., Nakamura H. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008, 199:455-462.
13. Teramoto T., Ohashi Y., Nakaya N., Yokoyama S., Mizuno K., Nakamura H. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA Study data. Circ J 2008, 72:1569-1575.
14. National Cholesterol Education Program Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) 1993, US Department of Health and Human Services, Washington, DC.
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
16. Nakamura T., Hirano M., Kitta Y., Fujioka D., Saito Y., Kawabata K., Obata J., Watanabe Y., Watanabe K., Kugiyama K. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol 2012, 60:12-17.
17. Uemura Y., Watarai M., Ishii H., Koyasu M., Takemoto K., Yoshikawa D., Shibata R., Matsubara T., Murohara T. Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012, 59:50-56.
18. Uchiyama S., Nakaya N., Mizuno K., Ohashi Y., Tajima N., Kushiro T., Teramoto T., Nakamura H. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci 2009, 284:72-76.
19. Matsushima T., Nakaya N., Mizuno K., Ohashi Y., Teramoto T., Yokoyama S., Ichikawa S., Ishikura N., Kamiyama K., Nakamura H. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post-hoc analysis of the MEGA Study. J Cardiovasc Pharmacol Ther 2012, 17:153-158. For the MEGA Study Group.